PAVmed Inc. (PAVM)
Market Cap | 46.30M |
Revenue (ttm) | 634,000 |
Net Income (ttm) | -90.33M |
Shares Out | 104.53M |
EPS (ttm) | -0.98 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,470,564 |
Open | 0.429 |
Previous Close | 0.425 |
Day's Range | 0.425 - 0.480 |
52-Week Range | 0.350 - 2.340 |
Beta | 0.85 |
Analysts | Buy |
Price Target | 1.50 (+238.68%) |
Earnings Date | May 16, 2023 |
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo,... [Read more]
Financial Performance
In 2022, PAVmed's revenue was $377,000, a decrease of -24.60% compared to the previous year's $500,000. Losses were -$89.26 million, 76.3% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 238.68% from the latest price.
News

PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
NEW YORK , June 2, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digi...

PAVmed Provides Business Update and First Quarter Financial Results
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomo...

Lucid Diagnostics Provides Business Update and First Quarter Financial Results
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST NEW YORK , May 15, 2023 /PRNewswire/ -- ...

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett'...

PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
NEW YORK, May 5, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnos...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medica...

PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digi...

PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS
Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m.

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer
Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard ...

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Conference call and webcast to be held tomorrow, March 15 th at 8:30 AM EST NEW YORK , March 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified comm...

PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023
NEW YORK, March 3, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagn...

PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live
Remote patient monitoring of first cohort of cancer patients using VerisBox™ connected devices and Veris CCP smartphone app initiated Cancer care team utilizing physiologic data and patient reported s...

PAVmed and Lucid Diagnostics Provide Strategic Business Update
NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health se...

PAVmed and Lucid Diagnostics to Provide Strategic Business Update
NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and ...

PAVmed Partners with Novosound on Ultrasound Imaging Technology
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health ...

Ultrasound Sensor Specialist Novosound Inks Deal With Nasdaq-listed PAVmed Inc. to Advance Intravascular Imaging Technology
GLASGOW, Scotland--(BUSINESS WIRE)--Ultrasound sensor specialist Novosound has signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, t...

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health ...

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVm...

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: P...

PAVmed Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, an...

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVme...

PAVmed to Participate in BTIG Digital Health Forum
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and d...

Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned su...

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned su...

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
NEW YORK--(BUSINESS WIRE)---- $PAVM #1x1meetings--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update ...